Patients With mCRPC Need Effective and Tolerable Treatments Earlier
PLUVICTO Is
Now Approved for More Patients
More of your patients may now be eligible for PLUVICTO. Learn more about the new indication.
Unmet Need
Not an actual patient.
- A majority of patients die within 2 years of an mCRPC diagnosis1
- More than half of patients with mCRPC will receive only one life-prolonging therapy2
- mCRPC is associated with fast progression, which can disrupt patients’ lives2,3
What if you could provide a different, targeted therapy EARLIER?
mCRPC, metastatic castration-resistant prostate cancer.
Mechanism of Action
PLUVICTO DELIVERS DNA-BREAKING RADIATION DIRECTLY TO PSMA+ METASTASES4
Learn how PLUVICTO works
Based on in vitro/in vivo studies. Preclinical activity does not correlate with clinical outcomes.
PLUVICTO targets PSMA+ cells regardless of where they have metastasized (bone, nodal, or visceral)4
PLUVICTO is comprised of 2 key components: Lutetium-177, a cytotoxic radionuclide, and PSMA-617, a PSMA-targeting ligand.4-6
PLUVICTO binds to PSMA, a transmembrane protein expressed in prostate cancer cells. After binding to PSMA, PLUVICTO undergoes endocytosis and is internalized into the cell.4,5,7
Lutetium-177, the cytotoxic radionuclide of PLUVICTO, emits DNA-breaking radiation within the cell. The short path length of the radiation emitted by PLUVICTO, approximately 2 millimeters maximum, causes single- and double-stranded DNA breaks in targeted cells as well as surrounding cells, which can lead to cell death.4,8,9
PLUVICTO (plu-VICK-toh) describes a PSMA-targeted (P) lutetium-based (LU) radioligand therapy in PSMA+ mCRPC, where another option for patients is a victory4
Scanning to confirm PSMA+ mCRPC is key to identifying patients who may benefit from PLUVICTO4
Find information on PSMA-PET/CT scanning for your patients
CT, computed tomography; PET, positron emission tomography; PSMA, prostate-specific membrane antigen; PSMA+, PSMA positive.